Table 4.
Prescriptions of S/V overall and S/V with SGLT2i according to prescribing specialty.
| Physician | Drug(s) | Variable | 2016 |
2017 |
2018 |
2019 |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | |||
| Primary care physician | S/V | Share of officesa (%) | 3.3 | 13.1 | 20.3 | 26.0 | 29.8 | 34.7 | 38.6 | 40.6 | 45.2 | 48.2 | 51.5 | 54.0 | 57.4 | 61.6 | 65.0 | 67.3 |
| Number of patients per office (n) | 1.3 | 1.4 | 1.5 | 1.6 | 1.7 | 1.8 | 1.8 | 2.0 | 2.0 | 2.2 | 2.3 | 2.4 | 2.6 | 2.9 | 3.1 | 3.3 | ||
| S/V + SGLT2i | Share of officesa (%) | 0.0 | 0.1 | 0.1 | 0.4 | 0.5 | 0.6 | 0.9 | 1.1 | 1.3 | 1.6 | 2.1 | 2.5 | 3.1 | 3.7 | 4.5 | 6.1 | |
| Number of patients per office (n) | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | ||
| Cardiologist | S/V | Share of officesa (%) | 29.2 | 54.6 | 65.3 | 69.9 | 69.5 | 71.2 | 75.5 | 77.7 | 79.2 | 80.6 | 79.6 | 81.0 | 79.0 | 79.3 | 80.5 | 84.0 |
| Number of patients per office (n) | 2.4 | 4.0 | 4.8 | 5.6 | 6.1 | 6.7 | 7.1 | 7.8 | 9.1 | 9.8 | 10.1 | 11.4 | 11.3 | 12.4 | 13.1 | 14.0 | ||
| S/V + SGLT2i | Share of officesa (%) | n/a | 0.9 | 1.4 | 2.3 | 0.9 | 1.7 | 0.9 | 2.6 | 2.8 | 4.0 | 4.1 | 5.9 | 5.7 | 7.1 | 7.4 | 11.6 | |
| Number of patients per office (n) | n/a | 1.0 | 1.0 | 1.0 | 1.0 | 1.3 | 1.5 | 1.2 | 1.0 | 1.1 | 1.1 | 1.1 | 1.2 | 1.1 | 1.2 | 1.3 | ||
| Physician | Drug(s) | Variable | 2020 |
2021 |
2022 |
2023 |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | |||
| Primary care physician | S/V | Share of officesa (%) | 71.0 | 72.1 | 74.5 | 75.6 | 76.4 | 78.3 | 80.2 | 81.3 | 81.0 | 81.0 | 80.9 | 80.6 | 84.4 | 84.1 |
| Number of patients per office (n) | 3.5 | 3.6 | 3.8 | 4.0 | 4.1 | 4.3 | 4.6 | 4.9 | 5.1 | 5.5 | 5.9 | 6.2 | 6.4 | 6.8 | ||
| S/V + SGLT2i | Share of officesa (%) | 8.3 | 8.5 | 9.8 | 12.1 | 15.7 | 20.7 | 29.4 | 39.3 | 45.0 | 50.8 | 54.5 | 57.2 | 63.1 | 65.2 | |
| Number of patients per office (n) | 1.1 | 1.1 | 1.1 | 1.1 | 1.2 | 1.2 | 1.3 | 1.5 | 1.7 | 1.9 | 2.0 | 2.2 | 2.4 | 2.5 | ||
| Cardiologist | S/V | Share of officesa (%) | 84.8 | 85.9 | 86.2 | 86.7 | 89.8 | 89.8 | 91.5 | 91.5 | 90.9 | 89.9 | 89.0 | 88.1 | 91.0 | 90.0 |
| Number of patients per office (n) | 14.9 | 14.4 | 15.1 | 16.1 | 16.0 | 16.4 | 16.7 | 18.2 | 18.3 | 19.0 | 19.2 | 20.0 | 19.6 | 19.6 | ||
| S/V + SGLT2i | Share of officesa (%) | 14.8 | 14.1 | 17.9 | 22.8 | 27.4 | 34.4 | 49.7 | 61.3 | 64.2 | 68.3 | 70.2 | 71.0 | 74.4 | 74.2 | |
| Number of patients per office (n) | 1.3 | 1.3 | 1.3 | 1.5 | 1.8 | 2.1 | 2.6 | 3.4 | 4.2 | 4.5 | 4.7 | 5.3 | 5.5 | 5.7 | ||
Primary care physician = general practitioner or general internist, S/V = sacubitril/valsartan, SGLT2i = sodium–glucose co-transporter 2 inhibitor, n/a = not available.
a
with at least one patient on drug.